Welcome to our dedicated page for Optimi Health news (Ticker: OPTHF), a resource for investors and traders seeking the latest updates and insights on Optimi Health stock.
Optimi Health Corp. (OPTHF) is a Health Canada-licensed manufacturer specializing in GMP-certified psychedelic substances for therapeutic research. This page provides investors and researchers with verified updates on the company’s regulatory progress, clinical partnerships, and production capabilities.
Access comprehensive coverage of Optimi Health’s developments including export agreements, compliance milestones, and research initiatives. Users will find press releases related to pharmaceutical-grade psilocybin production, MDMA formulation advancements, and international distribution partnerships across regulated markets.
Key updates focus on Health Canada licensing status, GMP manufacturing standards, clinical trial support, and strategic collaborations with global research organizations. All content is curated to meet investor needs for timely, accurate information in the evolving psychedelic pharmaceuticals sector.
Bookmark this page for streamlined access to Optimi Health’s official announcements. Check regularly for updates on regulatory approvals and advancements in psychedelic-assisted therapy research.
Optimi Health Corp. (OTCQB: OPTHF) launches its line of functional mushroom supplements in Canada, targeting health-conscious consumers. The products include Lion’s Mane, Reishi, Turkey Tail, Chaga, and Cordyceps, known for their health benefits. These supplements are created using a unique eight-hour extraction process to enhance efficacy. Optimi aims for vertical integration by cultivating its own mushroom strains in a new facility in Princeton, British Columbia. The company emphasizes high-quality production and customer accessibility through its website and upcoming retail partnerships.
Optimi Health Corp. (CSE: OPTI, OTCQB: OPTHF) has been added to Health Canada's approved suppliers under the Special Access Program (SAP) for psilocybin, aiming to address mental health issues in Canada. The SAP allows specific medical practitioners to request access to controlled substances for emergency use, paving the way for innovative treatments. The company’s new 10,000 sq. ft. facility in British Columbia has received supply requests, indicating strong market interest. Optimi is dedicated to safe and effective psilocybin products, with plans for a grand opening in May.
Optimi Health Corp. is on the path to becoming a leading all-natural psilocybin producer, following the acquisition of a Dealer’s License from Health Canada for its wholly-owned subsidiary, Optimi Labs Inc.
With a state-of-the-art 10,000 sq. ft. EU GMP-compliant facility in Princeton, B.C., Optimi is set to cultivate, extract, and process premium psilocybin. The facility can secure up to 1,250kg of psilocybin valued at approximately $53 million CAD.
Optimi aims to support mental health initiatives by supplying psilocybin to patients under the Special Access Program.
Optimi Health Corp. (CSE: OPTI) (OTCQB: OPTHF) has announced a second provisional patent for a novel two-part extraction and transdermal delivery method for psilocybin. This patented process isolates psilocybin using a viscous material, enhancing bioavailability by allowing the drug to penetrate the skin directly, avoiding liver metabolism. The technology provides a consistent and longer-lasting therapeutic experience, aligning with Optimi’s commitment to safe and sustainable psychedelic treatments.
Optimi Health Corp. (CSE: OPTI) (OTCQB: OPTHF) announces successful Health Canada inspection completion on December 21, 2021. The regulatory amendments to the Special Access Program (SAP) now allow practitioners to request access to psilocybin and MDMA for patients with serious conditions. This initiative aims to provide therapeutic options for treatment-resistant mental health issues. Optimi plans to lead in supplying GMP-certified psilocybin and has initiated its first clinical trial for micro-dosing psilocybin, pending Health Canada approval.
Optimi Health Corp. (CSE: OPTI, OTCQB: OPTHF) announced the initiation of a facility inspection by Health Canada and the establishment of a Quality Assurance department. The inspection is crucial for the future licensing of their mushroom facility in Princeton, BC, which has seen an investment of over CAD$8.5 million. The new department aims to ensure compliance with GMP standards, essential for the production of medicinal and psychedelic mushrooms. Key appointments include Raphael Moxam as Department Head and Farkhanda Saifullah Khowaja, Ph.D., as QA Manager, both bringing extensive industry experience.
Optimi Health Corp. (OTCQB: OPTHF) has announced the near completion of its Dealer’s License facility in Princeton, British Columbia, with final site inspections pending. Since December 2020, the company has invested over $8.5 million CAD in facility construction to ensure compliance with Health Canada's regulations. Optimi is also progressing with its analytical laboratory license, enhancing its capabilities for product testing and safety assurance. The company aims to establish itself as a leader in the production of functional and medicinal mushrooms, targeting the growing health and wellness sector.
Optimi Health Corp. (CSE: OPTI, OTCQB: OPTHF) announced its collaboration with Kydder Management Group Inc. to enhance its regulatory and corporate communications. Kydder Group will facilitate government relations, including leading a national coalition for psilocybin therapy access in Canada. CEO Bill Ciprick emphasized the importance of this partnership in aligning with regulatory standards and advancing the industry. Optimi aims to grow its presence in functional mushroom products and has facilities under construction in British Columbia.
Optimi Health Corp. (CSE: OPTI) (OTCQB: OPTHF) has appointed Dr. Valerie H. Taylor as the principal investigator for a phase I psilocybin clinical dosing study at the University of Calgary. Dr. Taylor, a leading expert in mental health innovation and research, will oversee the trial under a partnership with IMPACT Clinical Trial Accelerator. This initiative aims to advance research on psilocybin's potential therapeutic benefits, with plans to submit a formal dosing study application to Health Canada in Q4. This development highlights Optimi's commitment to exploring innovative mental health solutions.
Optimi Health Corp. (OTCQB: OPTHF) announced a patent filing for a novel extraction method that significantly enhances the yield of Psilocybin and Psilocin from mushrooms. This breakthrough process addresses the historical instability of these alkaloids, which can lose up to three times their alkaloid content when dehydrated. The new technique not only improves extraction efficiency but also protects the compounds from degradation, potentially lowering production costs and enhancing bioavailability. Additionally, the method embraces green chemistry principles, aligning with Optimi's sustainability goals.
